Beijing Hongtianli Pharmaceutical Co. Ltd.

A single-arm, open, multicenter clinical trial was designed to evaluate the safety and efficacy of Qinggan Jiangya Capsule in the treatment of essential hypertension (grade 1-2).

Using "mean daily intraocular pressure change relative to week 0 (baseline)" as the primary efficacy indicator, a randomized, double-blind, placebo-controlled, multicenter clinical trial design was adopted to evaluate the effectiveness and safety of Qinggan Jiangya Capsule in lowering intraocular pressure in primary open-angle glaucoma in a Phase II clinical trial, and conduct preliminary dose exploration.